Technology
Health
Pharmaceutical

Aquestive Therapeutics

$6.01
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.21 (-3.38%) Today
-$0.21 (-3.38%) Today

Why Robinhood?

You can buy or sell AQST and other stocks, options, ETFs, and crypto commission-free!

About

Aquestive Therapeutics, Inc. Common Stock, also called Aquestive Therapeutics, is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. Read More The company has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases, as well as orally-administered complex molecules that can be alternatives to invasively-administered standard of care therapies. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole). Aquestive Therapeutics develops and delivers drugs via its PharmFilm® technology. The firm also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the company, with its partners, has a portfolio of development-stage products and commercialized products, such as Suboxone, a prescription medicine for the treatment of opioid dependence. The company was founded in January 2004 and is headquartered in Warren, NJ.

Employees
Headquarters
Warren, New Jersey
Founded
2004
Market Cap
Price-Earnings Ratio
Dividend Yield
Average Volume
147.36K
High Today
$6.26
Low Today
$6.01
Open Price
$6.26
Volume
4.49K
52 Week High
$20.70
52 Week Low
$5.60

Collections

Technology
Health
Pharmaceutical
Therapy
Medical
2018 IPO
US
North America

News

Simply Wall StMar 21

Have Insiders Been Buying Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares This Year?

We’ve lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we’d be remiss not to mention that insider sales have been known to precede tough periods for a business. So we’ll take a look at whether insiders have been buying or selling shares in Aquestive Therapeutics, Inc. (NASDAQ:AQST). What Is Insider Selling? It’s quite normal to see company insiders, such as board members, trading in company stock, from time to time. However, su...

53
Seeking AlphaMar 15

Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q4 2018 Results - Earnings Call Transcript

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2018 Earnings Conference Call March 14, 2019 8:00 AM ET Company Participants Lauren Walrath - Head, Corporate Marketing and Communications Keith Kendall - Chief Executive Officer Ken Marshall - Chief Commercial Officer Dan Barber - Chief Strategy and Development Officer John Maxwell - Chief Financial Officer Conference Call Participants Gary Nachman - BMO Capital Markets Randall Stanicky - RBC Capital Markets Liana Moussatos - Wedbush Securities Dougl...

41
PR NewswireMar 14

Aquestive Therapeutics, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights

WARREN, N.J., March 14, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today reported financial results for the fourth quarter and full year ended December 31, 2018 and provided an update on recent developments in its business. "Aquestive made significant progress in 2018 by launching our first proprietary product and continuing our transformation into a com...

21

Earnings

-$0.56
-$0.54
-$0.53
-$0.51
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.51 per share
Actual
-$0.56 per share

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.